RGEN — Stock Film
STOCK FILMSCENE 1/11RGEN · $147
Stock Expert AI presents
RGEN
Repligen Corporation
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Repligen Corporation. A quick introduction.

On the stock market since 1986, it operates in the world of health and science. It has 2,000 employees. Now — the numbers.

on the stock market since 1986
2,000 employees
$8.3B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $7 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 7%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
50%Products
Products 50%Filtration Products 27%Chromatography Products 10%Proteins Products 7%Process Analytics Products 6%Other <1%
50% of all revenue comes from a single line: Products.

The biggest line carries real weight, but it doesn’t decide everything on its own.

What executives did with their own stock over the last 12 months:
35 buy34 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
75
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
75
strong

Clearly above the class average — a step short of the very top.

VALUATION
63
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
72
strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
61
average

The price is looking for direction — no strong breakout, no collapse.

No real weak spot in any of the five subjects — a balanced report card.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking8/10
A strong cash pile8/10
Few are betting against it10/10
WEAK SPOTS
The stock has lost its spark3/10
THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 55% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
Strong cash, light debt

There is $767.6M in the vault; even if every debt were paid off, $77.7M would remain.

2
THE BRIGHT SIDE · 2/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 35 buys and 34 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Sales are shrinking

Over the last 3 years, sales fell about 3% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.

2
THE RISKS · 2/2
A rich price tag

The company’s market value is 170 times its annual profit. Even a small disappointment could hit the price hard.

FINALE · THE GRADE
B
0 / 100 · MoonshotScore

On our five-subject report card, RGEN sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: RGEN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film